Facilities & Capabilities
Infrastructure built to translate liposomal systems from development into controlled, commercial-scale manufacture.
Integrated research, development and manufacturing within a single operational environment
Research & Analytical Capability
Development and analytical environments at GMPriority Pharma are designed to evaluate how lipid-based and liposomal systems behave under real formulation, processing and scale-up conditions.
Work is conducted with defined control over formulation variables, processing parameters and environmental conditions to ensure that delivery systems are characterised in ways that are relevant to manufacturing, not just laboratory performance.
Capabilities include:
- Lipid and liposomal formulation development across liquid and solid-state systems
- Structural and physicochemical characterisation, including particle size distribution (DLS), polydispersity index (PDI) and dispersion behaviour
- Encapsulation and loading assessment for active–lipid systems
- Stability testing under defined thermal, oxidative and storage conditions
- Compatibility assessment across excipients, formats and processing environments
Advanced analytical techniques, including Transmission Electron Microscopy (TEM), are applied selectively to support structural interpretation and formulation decision-making, not as standalone outputs, but as part of controlled delivery system design.
From Development to Scalable Production
Formulation development at GMPriority Pharma is conducted with manufacturing parameters, processing constraints and scale-up requirements defined from the outset.
Development environments are designed to:
- Evaluate delivery system behaviour under realistic formulation and processing conditions
- Identify scale-dependent constraints, including mixing, energy input and dispersion behaviour
- Support direct transfer from development into controlled production environments
This approach reduces reformulation risk and supports consistent performance as batch size, equipment and processing conditions evolve.
Controlled Production Environments
GMPriority Pharma operates GMP and FSSC ISO 22000-aligned production environments designed to support lipid-based systems through controlled processing and commercial manufacture.
Production capability includes:
- Bulk liposomal ingredient manufacture across liquid and dry formats
- Delivery-enabled ingredient programmes with defined formulation and process parameters
- Finished product manufacture where required, aligned with partner specifications
Manufacturing is governed through controlled process parameters, batch documentation and quality oversight systems designed to support reproducibility across production runs.
Rather than maximising throughput, the focus is on maintaining formulation integrity, process consistency and reliable output at commercial scale.
Process control and manufacturing execution are supported through GMPriority Pharma’s internal VEREx® framework, providing structured oversight of critical formulation and production parameters.
Integrated Infrastructure
GMPriority Pharma combines development, analytical and manufacturing capability within a single operational environment, enabling delivery systems to be designed, evaluated and produced under aligned conditions.
This integration supports:
- Direct transfer from development into manufacturing without reformulation
- Consistent batch performance through controlled process parameters
- Scale-up informed by equipment, processing and formulation constraints
- Reliable long-term supply supported by defined production and quality systems
This integrated model ensures that delivery systems are not only developed successfully but manufactured, controlled and supplied reliably at commercial scale.
